The immune microenvironment and heterogeneity of lung cancer tumours are the major barriers to immunotherapy, explains Lu. “We are looking to improve the efficacy of T cell therapy while ...

Active specific immunotherapy; BCG: Bacille Calmette–Guérin; KLH: Keyhole limpet hemocyanin; MPL: Monophosphoryl lipid A; NSCLC: Non-small-cell lung cancer. Various adjuvant products are ...

and lung. The term can apply to multiple types of specific therapies, including chemotherapy, radiation, hormone therapy, and ...

This may be the case with whole tumor vaccine strategies with detrimental outcome, such as GVAX immunotherapy ... larger multicenter adjuvant vaccine clinical trials in cancer patients are ...

Roche's drug is the first cancer immunotherapy to be approved by the FDA for adjuvant treatment of NSCLC ... and patients a new way to treat early lung cancer that has the potential to ...

Liu et al review the evolving landscape of adjuvant treatments in non–small-cell lung cancer, where in the advanced disease setting, there is a growing set of effective targeted therapies and ...

Experts from various tumor fields, including lung cancer, hepatobiliary ... effectiveness and high safety of the 'neo-adjuvant bladder preservation immunotherapy model' with Chinese characteristics.

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...